Показатели серотонина в биологических жидкостях как маркер диагностики и эффективности лечения нейроортопедических заболеваний
https://doi.org/10.20340/vmirvz.2021.5.CLIN.5
Аннотация
В данной статье рассмотрены вопросы изучения динамики изменения серотонина в биологических жидкостях как маркера при различных нейроортопедических заболеваниях у пациентов разного возраста. Для этого проведен анализ клинической практики. Сделан вывод о том, что изменение уровня серотонина может рассматриваться в качестве индикатора болевых ощущений и контроля проводимой терапии при нейроортопедических патологиях. Обозначена необходимость проведения дальнейшего углубленного изучения имеющейся практики оценки изменения уровня серотонина в биологических жидкостях в ходе консервативного лечения и после оперативного вмешательства в различных случаях нейроортопедических заболеваний у разновозрастных пациентов.
Ключевые слова
Об авторах
М. Е. Виндерлих
Марийский государственный университет
Россия
Россия
Виндерлих Марина Евгеньевна, доцент кафедры педиатрии, Медицинский институт
Йошкар-Ола
Н. Б. Щеколова
Пермский государственный медицинский университет имени академика Е.А. Вагнера
Россия
Россия
Щеколова Наталья Борисовна, доктор медицинских наук, профессор, профессор кафедры травматологии, ортопедии и нейрохирургии
Пермь
Список литературы
1. Borisova L.I. Spinal canal stenosis: clinical neurology, quality of life and humoral serotonin before and after surgical treatment: dis. ... cand. honey. sciences. Perm, 2012.183 p. (In Russ).
2. Gorozhaninova E.V., Loginova N.V. Assessment of humoral serotonin, pain and mental status of patients with spastic torticollis. Materials of the 93rd final scientific-practical conference of students, residents, graduate students, young scientists (up to 35 years old) "Young science – practical health care". PSMU named after academician E.A. Wagner. April 13-17, 2020 Perm: Perm State Medical University. 2020:52-55. (In Russ).
3. Gorina A.S., Goetze S., Kolesnichenko L.S. Age-related dynamics of monoaminoergic neurotransmitters in cerebrospinal fluid in autism, attention deficit hyperactivity disorder and their comorbidity. Siberian Medical Journal (Irkutsk). 2013;117(2):34-37. (In Russ).
4. Kazakova M.S. The influence of the therapeutic factors of the Klyuchi resort on pain. psychovegetative status and humoral serotonin in patients with cervical dorsopathy: author. dis. ... cand. honey. sciences. Perm, 2009. 21 p. (In Russ).
5. Karakulova Yu. V. Serotonin system of peripheral blood of patients with tension headache (clinical and biochemical study): dis. … doc. honey. sciences. Perm, 2006. 239 p. (In Russ).
6. Kushlinsky N.E., Lyubimova N.V. Biochemical markers in the diagnosis of neuroendocrine tumors. Clinical laboratory diagnostics. 2014;7:4-11. (In Russ).
7. Lobzin S.V [and others]. Some indicators of dysfunction of neurotransmitter systems in dystonia and essential tremor. Bulletin of the North-Western State Medical University named after I. I.I. Mechnikov. 2016;6(2): 38-41. (In Russ).
8. Loginova N.V. Clinical characteristics of hyperkinesis and peripheral blood serotonin in patients with focal muscular dystonia before and after botulinum therapy: dis. ... cand. honey. sciences. Perm, 2019.153 p. (In Russ).
9. Lychkova A.E., Puzikov A.M. Prolactin and serotonin. Bulletin of the Russian Academy of Medical Sciences. 2014;69(1–2):38-45. (In Russ).
10. Mikheeva I.G., Ryukert E.N., Brusov O.S. et al. Serotonin content in blood serum of newborns with hypoxicischemic lesions of the central nervous system Pediatrics. 2008;87(1):40-44. (In Russ).
11. Sheibak L. N., Katkova E. V. Serotonin and its derivatives in umbilical cord blood serum of premature newborns. Russian Bulletin of Perinatology and Pediatrics. 2010;4:27-30. (In Russ).
12. Striebel H.V. Chronic Pain Therapy: A Practical Guide. Moscow: GEOTAR-Media, 2015. 304 p. (In Russ).
13. Ardill J.E. Circulating markers for endocrine tumours of the gastroenteropancreatic tract. Annals of Clinical Biochemistry. 2008;45(6):539-559.
14. Benekareddy, M., Vadodaria, K. C., Nair, A. R., and Vaidya, V. A. Postnatal serotonin type 2 receptor blockade prevents the emergence of anxiety behavior, dysregulated stress-induced immediate early gene responses, and specific transcriptional changes that arise following early life stress. Biol. Psychiatry. 2011;70:1024-1032. https://doi.org/10.1016/j.biopsych.2011.08.005
15. Booij L., Tremblay R.E., Szyf M. and Benkelfat C. Genetic and early environmental influences on the serotonin system: consequences for brain development and risk for psychopathology. J. Psychiatry Neurosci. 2015;40:5–18. https://doi.org/10.1503/jpn.140099
16. Boukhris T., Sheehy O., Mottron L. and Berard A. Antidepressant use during pregnancy and the risk of autism spectrum disorder in children. JAMA Pediatr. 2015;70:117-124. https://doi.org/10.1001/jamapediatrics.2015.3356
17. Brummelte S., Mc Glanaghy E., Bonnin A., Oberlander T.F. Developmental changes in serotonin signaling: implications for early brain function, behavior and adaptation. Neuroscience. 2017;342:212-231.PMID: 26905950 https://doi.org/10.1016/j.neuroscience.2016.02.037
18. Dankoski E.C., Carroll S. and Wightman R.M. Acute selective serotonin reuptake inhibitors regulate the dorsal raphe nucleus causing amplification of terminal serotonin release. J. Neurochem. 2016;136: 1131- 1141. https://doi.org/10.1111/jnc.13528
19. Dorszewska J., Florczak-Wyspianska J., Kowalska M. et al. Serotonin in Neurological Diseases InTech, 2017, https://doi.org/10.5772/intechopen.69035
20. Igelstrom KM Preclinical antiepileptic actions of selective serotonin reuptake inhibitors--implications for clinical trial design. Epilepsia. 2012;53(4):596-605. PMID: 22416943 https://doi.org/10.1111/j.1528-1167.2012.03427.x
21. Faingold C.L., Tupal S., & Randall M. Prevention of seizure-induced sudden death in a chronic SUDEP model by semichronic administration of a selective serotonin reuptake inhibitor. Epilepsy Behav. 2011;22(2): 186-190. PMID: 21920504 https://doi.org/10.1016/j.brainres.2011.08.043
22. Ghevariya V. [et al.] Carcinoid tumors of the gastrointestinal tract. South Med J. 2009;102(10):1032-1040.
23. Herman S, ?kerfeldt T, Spjuth O, Burman J, Kultima K. Biochemical differences in cerebrospinal fluid between secondary progressive and relapsing-remitting multiple sclerosis. 2019;8:84. PMID: 30678351 https://doi.org/10.3390/cells8020084
24. Homberg JR, Lesch KP. Looking on the bright side of serotonin transporter gene variation. Biol Psychiatry. 2011;69:513519. PMID: 21047622 https://doi.org/10.1016/j.biopsych.2010.09.024
25. Homberg JR, Schubert D, Gaspar P. New perspectives on the neurodevelopmental effects of SSRIs. Trends Pharmacol Sci. 2010;31:60-65. PMID: 19963284 https://doi.org/10.1016/j.tips.2009.11.003
26. Lesurtel M. [et al.] A role of serotonin in the hepatogastrointestinal tract: an old molecule for new perspectives. Cell Mol Life Sci., 2008;65(6):940-52. PMID: 18080089 https://doi.org/10.1007/s00018-007-7377-3
27. Miller J.M., Kinnely E.L. et al. Reported childhood abuse is associated with low serotonin transporter binding in vivo in major depressive disorder, 2009;63(7):565-573. https://doi.org/10.1002/syn.20637
28. Sargin D., Jeoung H.-S., Goodfellow N.M. and Lambe, E.K. Serotonin regulation of the prefrontal cortex: cognitive relevance and the impact of developmental perturbation. ACS Chem. Neurosci. 2019;10: 3078- 3093. https://doi.org/10.1021/acschemneuro.9b00073
29. Shah R., Courtiol E., Castellanos F.X., Teixeira C.M. Abnormal serotonin levels during perinatal development lead to behavioral deficits in adulthood. Frontiers in Behavioral Neuroscience. 2018, no. 12, Article 114, https://doi.org/10.3389/fnbeh.2018.00114
30. Zhang T, Kingwell E, De Jong HJ et al. Association between the use of selective serotonin reuptake inhibitors and multiple sclerosis disability progression. Pharmacoepidemiol Drug Saf. 2016;25:1150-1159. PMID: 27211481 https://doi.org/10.1002/pds.4031
Рецензия
Для цитирования:
Виндерлих М.Е., Щеколова Н.Б. Показатели серотонина в биологических жидкостях как маркер диагностики и эффективности лечения нейроортопедических заболеваний. Вестник медицинского института «РЕАВИЗ». Реабилитация, Врач и Здоровье. 2021;11(5):105-112. https://doi.org/10.20340/vmirvz.2021.5.CLIN.5
For citation:
Winderlich M.E., Shchekolova N.B. Serotonin level in biological fluids as a marker of neuroorthopedic diseases diagnostics and treatment efficiency. Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH). 2021;11(5):105-112. (In Russ.) https://doi.org/10.20340/vmirvz.2021.5.CLIN.5
Просмотров:
436
Послать статью по эл. почте 